President and Chief Executive Officer
Jerry Williamson brings more than 30 years of commercial operating, business development and corporate management experience in the diagnostic and life science marketplace where he has held executive leadership roles responsible for value creation, growth and profitability. Most recently, Jerry was President and CEO of Metamark Genetics, Inc., a private molecular diagnostics company, which he joined in 2015.
Prior to Metamark, Jerry was a Partner with Flagship Ventures focused on building and developing relationships with corporate partners for the firm’s core innovation and investment activities. He was President of Global Commercial Operations for Genetix Ltd., a UK-based bioresearch imaging company that was sold to Danaher and merged with Molecular Devices where Jerry served as Vice President and General Manager. As President of Biacore, Inc., Jerry ran the North American subsidiary of this European biotech instrument supplier, where he was also responsible for post-acquisition integration into GE Healthcare. Jerry was also President of Pyrosequencing, Inc., the US subsidiary of a Swedish-led DNA sequencing platform provider.
Jerry received a BS degree in Biochemistry from the University of Vermont and holds an MBA degree from Boston University.
H. Robert Horvitz, PhD
An investigator at the Howard Hughes Medical Institute and David H. Koch professor in the MIT Department of Biology, Dr. Horvitz was awarded the Nobel Prize in Physiology or Medicine in 2002.
Mr. Miller received his B.S. in Nuclear Engineering from the University of Massachusetts, and received his Masters of Science degree from the Harvard-MIT Program in Health Sciences and Technology. A seasoned executive in the diagnostic space, Mr. Miller previously served as Chief Executive Officer (CEO) of Siemens Healthcare’s Customer Solutions Division, responsible for an organization of 26,000 employees in over 130 countries. He also held other leadership roles during his tenure at Siemens, including serving as a member of the Group Board of Siemens Medical Solutions, as well as overseeing the company’s global MRI business. In addition, Mr. Miller has served as CEO for several other organizations, including Global Medical Operations of Carl Zeiss, Inc.; Analogic Corporation; and LightLab Imaging, a start-up he helped to establish and sell, and for whom he also served as Chairman. In April 2013, he founded GreyBird Ventures, a consultancy and investment firm, where he currently serves as director, advisor, and/or investor in six healthcare start-up companies.
Mr. Simoncini has over 10 years of experience in Healthcare. He is currently leading strategy and business development for Cardinal Health Specialty Solutions. Previously Mr. Simoncini held various positions in investment banking at Bank of America Merrill Lynch and RBC Capital Markets, and worked in corporate finance and strategic planning at Pfizer, Inc. He holds an MBA from Harvard Business School, a Master's degree in Public Health from Columbia University and a Bachelor's degree from the University of Virginia.
Valerie Friedman, MBA
Ms. Friedman is currently a principal at a Boston-based hedge fund.
Mrs. Erony has more than 25 years experience as a principal in investing activities, investment banking and business development. She is currently a Director of ImpoPharma, IGI Labs and Fluxion and has been a Director of Peak Surgical (acquired by Medtronic), Dow Pharmaceutical Sciences (acquired by Valeant), Atlantis Components (acquired by AstraZeneca) , and Control Delivery Systems (acquired by Psivida).
Previously, Mrs. Erony was a strategic advisor to Alcon Labs and was a Managing Director at Citigroup responsible for the Bank’s activities in specialty pharmaceuticals and medical technologies.
Raju Kucherlapati, PhD
KEW Founder, Board Member
Founder and board member of KEW, Inc. Dr. Kucherlapati currently serves as the Paul C. Cabot Professor of Genetics and Professor of Medicine, Harvard Medical School Director Emeritus, Harvard Medical School-Partners HealthCare Center for Personalized Genetic Medicine and Principal Investigator at the Genome Characterization Center. Dr. Kucherlapati also serves as a member of the Presidential Commission for the Study of Bioethical Issues, was a key contributor to the groundbreaking Human Genome Project and a contributing author of the published results.
Tuan Ha-Ngoc has more than 30 years of senior leadership experience in the biotech industry. In June 2015, he was appointed executive chairman of KEW, Inc. a molecular profiling company utilizing Next Generation Sequencing technology with a mission of bringing Precision Medicine to All. From January to November 2015, Mr. Ha-Ngoc was the chairman of the Board of AVEO Pharmaceuticals, Inc., a company dedicated in the discovery and development of novel cancer medicines, having been its president and CEO since the beginning in 2002. From 1999 to 2002, he was co-founder, president and chief executive officer of deNovis, Inc., an enterprise-scale software development company for the automation of healthcare administrative functions. From 1998 to 1999, Mr. Ha-Ngoc was corporate vice president of strategic development for Wyeth, following Wyeth’s acquisition of Genetics Institute, where Mr. Ha-Ngoc served from 1984 to 1997 as executive vice president with responsibility for corporate development, commercial operations and European and Japanese operations. From 1976 to 1984, he served in various management capacities with Baxter Health Care first at their European headquarters then at their corporate offices in Deerfield, IL. He holds an M.B.A. from INSEAD and an M.A. in pharmacy from the University of Paris, France.